Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MK-1084
i
Other names:
MK-1084, MK 1084, MK1084
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Merck (MSD), Otsuka
Drug class:
KRAS G12C inhibitor
Related drugs:
‹
sotorasib (76)
adagrasib (35)
garsorasib (6)
RG6330 (6)
glecirasib (4)
fulzerasib (4)
ZG19018 (4)
APG-1842 (3)
ARS-1620 (2)
BI 1823911 (2)
JDQ443 (2)
ABSK071 (1)
AZ’8037 (1)
GEC-255 (1)
RM-029 (1)
YL-17231 (1)
D3S-001 (0)
GH35 (0)
HS-10370 (0)
JNJ-74699157 (0)
LY3499446 (0)
UCT-001024 (0)
VRTX126 (0)
YL-15293 (0)
RMC-6291 (0)
LY3537982 (0)
HBI-2438 (0)
sotorasib (76)
adagrasib (35)
garsorasib (6)
RG6330 (6)
glecirasib (4)
fulzerasib (4)
ZG19018 (4)
APG-1842 (3)
ARS-1620 (2)
BI 1823911 (2)
JDQ443 (2)
ABSK071 (1)
AZ’8037 (1)
GEC-255 (1)
RM-029 (1)
YL-17231 (1)
D3S-001 (0)
GH35 (0)
HS-10370 (0)
JNJ-74699157 (0)
LY3499446 (0)
UCT-001024 (0)
VRTX126 (0)
YL-15293 (0)
RMC-6291 (0)
LY3537982 (0)
HBI-2438 (0)
›
Associations
(2)
News
Trials
Filter by
Latest
1d
A Clinical Study of MK-1084 With Rosuvastatin and Metformin in Healthy People (MK-1084-016) (clinicaltrials.gov)
P1, N=16, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
1 day ago
Enrollment open
|
metformin • MK-1084
6d
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (clinicaltrials.gov)
P2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC
6 days ago
New P2 trial
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed • MK-1084
1m
A Clinical Study of MK-1084 With Rosuvastatin and Metformin in Healthy People (MK-1084-016) (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Merck Sharp & Dohme LLC
1 month ago
New P1 trial
|
metformin • MK-1084
1m
A Study of MK-1084 in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) (clinicaltrials.gov)
P1, N=58, Not yet recruiting, Merck Sharp & Dohme LLC
1 month ago
New P1 trial
|
MK-1084
1m
A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (clinicaltrials.gov)
P3, N=675, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
1 month ago
Enrollment open
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • MK-1084
1m
A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011) (clinicaltrials.gov)
P1, N=52, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
1 month ago
Trial completion
|
MK-1084
2ms
KANDLELIT-014: A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014) (clinicaltrials.gov)
P2, N=150, Not yet recruiting, Merck Sharp & Dohme LLC
2 months ago
New P2 trial • Pan tumor
|
KRAS (KRAS proto-oncogene GTPase)
|
Erbitux (cetuximab) • MK-1084
2ms
A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (clinicaltrials.gov)
P3, N=675, Not yet recruiting, Merck Sharp & Dohme LLC
2 months ago
New P3 trial
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • MK-1084
4ms
A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov)
P3, N=477, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2031 --> Oct 2030
4 months ago
Trial completion date
|
KRAS (KRAS proto-oncogene GTPase)
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium
4ms
A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov)
P3, N=477, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
4 months ago
Enrollment open
|
KRAS (KRAS proto-oncogene GTPase)
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium
6ms
A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011) (clinicaltrials.gov)
P1, N=52, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
6 months ago
Enrollment closed
|
MK-1084
6ms
A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov)
P3, N=477, Not yet recruiting, Merck Sharp & Dohme LLC
6 months ago
New P3 trial
|
KRAS (KRAS proto-oncogene GTPase)
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.